Sotio Biotech, a clinical stage immuno-oncology company owned by PPF Group, has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., through its subsidiaries, to evaluate the combination of SOT101, Sotio’s IL-15 superagonist, and MSD’s Keytruda (pembrolizumab) in patients with selected advanced/refractory solid tumors in the phase 2 Aurelio-04 study.   “SOT101 in combination with Keytruda has shown promising clinical ...